MassTarget™ Platform
MassTarget™ combines chemoproteomics, thermal proteomics, imaging, high-throughput MS, and multi-omics to support research-only drug discovery programs from early target discovery to hit-to-lead.
3
Integrated discovery paths
150+
MS-based modules
End-to-end
From disease → target → drug
Tech Platform
MS technologies for binding, stability, imaging, and high-throughput screening.
Drug Discovery Solutions
Workflows for Disease → Target, Drug → Target, and Target → Drug projects.
Case Studies & Resources
Data-driven applications, whitepapers, and project examples.
Supporting discovery teams across pharma, biotech, and academic centers with MS-based target ID, degrader projects, and screening programs.
>120
discovery MS projects
>60
target ID / MoA studies
10+ yrs
proteomics & MS experience
DRUG DISCOVERYSOLUTIONS
MassTarget™ supports three complementary discovery strategies: starting from disease biology, from phenotypic hits, or from known targets. Each path is powered by a tailored combination of MS technologies.
The platform links samples, MS modules, and decision points along the drug discovery cycle.
Path 01
Disease → Target
Path 02
Drug → Target
Path 03
Target → Drug
Starting from patient cohorts or preclinical models, we use quantitative proteomics and multi-omics to define pathways and convert biomarkers into actionable therapeutic targets.
For phenotypic hits, PROTACs, and molecular glues, we map target engagement, off-targets, and mechanisms of action directly in complex proteomes and cells using MS-based chemoproteomics and thermal proteomics.
When the target is known, MassTarget™ builds MS-based assays for fragment and covalent screening, biophysical validation, and high-throughput profiling to feed medicinal chemistry with clean hits and mechanistic data.
MassTarget Tech Platform
The platform is organized into modular MS capabilities that can be combined for custom programs or used as stand-alone services.
Direct binding and affinity assessment without labels in native or complex matrices.
Activity- and reactivity-based profiling to map ligandable and covalent sites proteome-wide.
Thermal shift and footprinting MS to report on conformational and stability changes upon binding.
Pull-down, proximity labeling, and complex-centric MS to capture direct and network-level targets.
From intact cells and organoids to spatial MSI for drug distribution and engagement.
Label-free, miniaturized MS readouts for enzyme panels and hit discovery.
Mass spectrometry-based ADME, metabolite ID, and PK profiling to support early discovery.
Integrated proteomics, metabolomics, PTM-omics, and modeling to interpret MS data in pathway context.
Featured Techniques
Selected MassTarget™ modules that frequently appear in small-molecule, PROTAC, and molecular glue programs. Each technique can be requested as a stand-alone study or embedded into integrated workflows.
Map ligandable residues across enzyme families and triage covalent hits with proteome-wide selectivity data.
Detect conformational changes and binding regions directly in native lysates without protein purification.
Proteome-wide melting curves to quantify target engagement, selectivity, and off-target liabilities.
Combine CETSA-MS, native MS, and ubiquitinomics to characterize ternary complexes and degradation profiles.
Featured Case Study
Working with a global oncology team, MassTarget™ combined LiP-MS, TPP, and competitive ABPP to map on- and off-target engagement directly in primary tumor samples, helping the sponsor interpret clinical safety signals and prioritize follow-up candidates.
Phase I KRAS G12C inhibitor program · Top 20 pharma partner MassTarget™ Chemoproteomics & Thermal Proteome Profiling Workflow
Resources
Downloadable resources designed to help you explain MS-based workflows to internal stakeholders and plan the right experiments for your project.
A practical guide to combining ABPP, LiP-MS, TPP, and CETSA-MS in a single target ID program, from hit nomination through orthogonal validation.
Includes example study designs, sample considerations, and typical data outputs for small molecules, PROTACs, and molecular glues.
Download PDF
Send to my inbox
CETSA-MS, TPP, ubiquitinomics, and native MS workflows for degrader engagement and selectivity.
PDF
APEX/BioID, CETSA-MS, and ubiquitinomics for glue-induced binding events and degradation profiles.
PDF
RapidFire, AEMS, and enzymatic panels for high-throughput hit evaluation beyond optical readouts.
PDF
MALDI-MSI and DESI-MSI for mapping tissue penetration, exposure, and on-target biology in discovery.
PDFCollaboration
From pilot studies to program-level support, we design MS workflows around your questions, assets, and internal decision points.
01
Project discussion
Clarify disease area, modality, questions, and available samples.
02
Study design
Assemble MS modules (chemoproteomics, thermal, imaging, HT-MS) into a tailored plan.
03
Experimental execution
Run MS workflows with QC and reference controls aligned with discovery needs.
04
Data interpretation
Translate spectra into targets, networks, and MoA stories suitable for internal review.
05
Follow-up & iteration
Plan orthogonal validation and next experiments with your team.
Receive timelines, deliverables, and a tailored workflow proposal.
Resources
Use these resources to align internal stakeholders and plan MS-enabled drug discovery campaigns.
A concise overview of ABPP, LiP-MS, TPP/PISA, CETSA-MS, and complementary methods, with decision trees for different chemotypes and target classes.
Download the whitepaperHow to combine ternary complex analysis, ubiquitinomics, and degradation profiling in a staged way.
Download guide
When to add MALDI / DESI imaging, what samples you need, and what decisions it can support.
Download guide
About MassTarget™
Purpose-built labs, instruments, and informatics to keep complex MS projects on track.
MassTarget™ combines mass spectrometry, proteomics, structural biology, and chemoproteomics expertise into one platform.
Our teams bring together scientists with deep experience in proteomics, biophysics, enzymology, and drug discovery. We operate dedicated MS labs equipped with high-resolution LC-MS/MS systems, native MS, imaging MS, and high-throughput interfaces.
FAQ
How early can we get involved?
Some partners bring us in with only a disease model and rough compound ideas; others already have hits, PROTACs, or glues and need deeper mechanistic support.
Either way, the first step is a short conversation about your biology, current data, and decision points. From there, we outline an MS plan and refine it together.
How much material do you typically need?
It depends on the technology module. For example, discovery-scale chemoproteomics and TPP/PISA can often start from millions of cells or small tissue amounts, while imaging MS requires appropriately prepared sections. During scoping we provide concrete input on sample numbers, controls, and replicates.
Can you support both exploratory and GLP-like workflows?
MassTarget™ is primarily designed for discovery and mechanism-focused work. Within that scope, we build robust SOPs, run QC, and deliver structured data and documentation suitable for internal governance and due diligence reviews.
What if we only know we have a phenotype but no clear targets?
That is exactly where the Disease → Target path applies. We can start with unbiased proteomics, phosphoproteomics, and interactome profiling, then converge on ranked target hypotheses and validation options.
Do you work with both in-house and external chemistry teams?
Yes. We frequently collaborate with organizations that have internal medicinal chemistry and with those who outsource chemistry. Our role is to provide the MS-based evidence that guides structure–activity relationships, triages hits, and supports mechanism discussions.
